National Institutes of Health: Breast Neoplasms trials

The registry lists 285 Breast Neoplasms studies with National Institutes of Health as lead sponsor. 21 are open to participants now and 80 have results posted.

Early Phase 1 3Phase 1 99Phase 2 115Phase 3 20No phase 69(a study in two phases counts in both)

Studies

Page 1 of 3. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain MetastasesRecruitingNCT07619534
• Natural History Study of Early Life Exposures in Agriculture (ELEA)Enrolling by invitationNCT07328516
• Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast CancerRecruitingNCT07137416Phase 1
• A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)RecruitingNCT07067138Not applicable
• The Vanguard Study: Testing a New Way to Screen for CancerRecruitingNCT06995898Not applicable
• Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk ReductionRecruitingNCT06195306Phase 2
• Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE TrialRecruitingNCT06184750Phase 2
• Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast CancerRecruitingNCT05941520Phase 2
• Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid TumorsRecruitingNCT05372640Phase 1
• Tissue Acquisition and Genomics Analysis of Breast Cancer and Other Gynecologic MalignanciesEnrolling by invitationNCT03762733
• Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic CancerRecruitingNCT03412877Phase 2
• Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing CancersRecruitingNCT02830724Phase 1/2
• Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast CancerRecruitingNCT02610439
• Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast CancerRecruitingNCT02610426
• Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast CancerRecruitingNCT02610413
• Genomic Services Research ProgramRecruitingNCT02595957
• Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic AnalysisRecruitingNCT01441089
• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic CancerRecruitingNCT01174121Phase 2
• Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer StudiesRecruitingNCT00451022
• Harvesting Cells for Experimental Cancer TreatmentsEnrolling by invitationNCT00068003
• Collection of Blood From Patients With CancerRecruitingNCT00034216
• Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal CarcinomatosisCompletedNCT05185947Phase 2Results posted
• BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)TerminatedNCT04296942Phase 1Results posted
• Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast CancerTerminatedNCT04108858Phase 1/2Results posted
• Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast CancerActive, not recruitingNCT03939897Phase 1Results posted
• ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial CarcinomaCompletedNCT03394027Phase 2Results posted
• Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast CancerCompletedNCT03323658Phase 1Results posted
• Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast SurgeryActive, not recruitingNCT03317405Phase 1Results posted
• PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by SurgeryCompletedNCT03218826Phase 1Results posted
• Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast CancerTerminatedNCT03199885Phase 3Results posted
• T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic RadiosurgeryTerminatedNCT03190967Phase 1/2Results posted
• Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast CancerCompletedNCT02898207Phase 1Results posted
• Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast CancerActive, not recruitingNCT02883062Phase 2Results posted
• Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast CancerTerminatedNCT02876640Phase 1Results posted
• Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast CancerCompletedNCT02598557Phase 2Results posted
• Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain MetastasesCompletedNCT02595905Phase 2Results posted
• A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid TumorsActive, not recruitingNCT02498613Phase 2Results posted
• Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast CancerActive, not recruitingNCT02311933Phase 2Results posted
• A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate CancerTerminatedNCT02203513Phase 2Results posted
• Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or MetastaticActive, not recruitingNCT02115282Phase 3Results posted
• Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast CancerCompletedNCT02003209Phase 3Results posted
• Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast CancerCompletedNCT01964924Phase 2Results posted
• Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer SurvivorsCompletedNCT01849250Phase 2Results posted
• Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast CancerTerminatedNCT01776008Phase 2Results posted
• Ad/HER2/Neu Dendritic Cell Cancer Vaccine TestingCompletedNCT01730118Phase 1Results posted
• Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast CancerCompletedNCT01688609Phase 2Results posted
• Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast CancerCompletedNCT01622868Phase 2Results posted
• Tivantinib in Treating Patients With Recurrent or Metastatic Breast CancerCompletedNCT01575522Phase 2Results posted
• Imaging Study for FdCyd and THU Cancer TreatmentTerminatedNCT01479348Early Phase 1Results posted
• Azacitidine and Entinostat in Treating Patients With Advanced Breast CancerCompletedNCT01349959Phase 2Results posted
• MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast CancerTerminatedNCT01319539Phase 2Results posted
• Phase II ABT-888 With CyclophosphamideCompletedNCT01306032Phase 2Results posted
• Akt Inhibitor MK2206 in Treating Patients With Advanced Breast CancerCompletedNCT01277757Phase 2Results posted
• Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast CancerCompletedNCT01275677Phase 3Results posted
• RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast CancerTerminatedNCT01217411Phase 1/2Results posted
• Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast CancerTerminatedNCT01151449Phase 2Results posted
• Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast CancerCompletedNCT01149083Phase 2Results posted
• Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast CancerCompletedNCT01142401Phase 2Results posted
• A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)CompletedNCT00978250Phase 2Results posted
• Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by SurgeryCompletedNCT00861705Phase 2Results posted
• Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast CancerCompletedNCT00785291Phase 3Results posted
• Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by SurgeryCompletedNCT00770809Phase 3Results posted
• Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast CancerCompletedNCT00699491Phase 1/2Results posted
• Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast CancerCompletedNCT00684983Phase 2Results posted
• F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast CancerCompletedNCT00602043Phase 2Results posted
• Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast CancerCompletedNCT00601900Phase 3Results posted
• Phase II Study of Fluorine-18 3'-Deoxy-3'-Fluorothymidine (F-18-FLT) in Invasive Breast CancerCompletedNCT00572728Phase 2Results posted
• Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By SurgeryCompletedNCT00559507Phase 2Results posted
• Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In SituCompletedNCT00555152Not applicableResults posted
• Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEUTerminatedNCT00520975Phase 3Results posted
• Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by SurgeryCompletedNCT00513292Phase 3Results posted
• Pazopanib in Treating Patients With Recurrent or Metastatic Breast CancerCompletedNCT00509587Phase 2Results posted
• Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast CancerCompletedNCT00470301Phase 1/2Results posted
• Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-PositiveCompletedNCT00390455Phase 3Results posted
• Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast CancerCompletedNCT00376688Phase 2Results posted
• VEGF Trap in Treating Patients With Metastatic Breast CancerCompletedNCT00369655Phase 2Results posted
• Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast CancerCompletedNCT00368875Phase 1/2Results posted
• Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)Active, not recruitingNCT00310180Phase 3Results posted
• Genistein in Preventing Breast Cancer in Women at High Risk for Breast CancerCompletedNCT00290758Phase 2Results posted
• Vorinostat in Treating Women Who Are Undergoing Surgery For Newly Diagnosed Stage I -III Breast CancerCompletedNCT00262834Phase 2Results posted
• Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast CancerCompletedNCT00258349Phase 1/2Results posted
• A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)CompletedNCT00244881Phase 2Results posted
• Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast CancerCompletedNCT00217399Phase 1/2Results posted
• Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian CancerCompletedNCT00182767Phase 1/2Results posted
• Docetaxel Alone or in Combination With Vaccine to Treat Breast CancerCompletedNCT00179309Phase 2Results posted
• Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast CancerTerminatedNCT00132002Phase 2Results posted
• Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast CancerCompletedNCT00119262Phase 2Results posted
• Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous TamoxifenCompletedNCT00118157Phase 2Results posted
• Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast CancerTerminatedNCT00096109Phase 2Results posted
• S0338, Imatinib Mesylate and Capecitabine in Treating Women With Progressive Stage IV Breast CancerCompletedNCT00087152Phase 2Results posted
• Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast CancerCompletedNCT00082810Phase 2Results posted
• Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast CancerTerminatedNCT00079326Phase 2Results posted
• Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast CancerCompletedNCT00077376Phase 2Results posted
• GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast CancerCompletedNCT00068588Phase 2Results posted
• Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast CancerTerminatedNCT00063934Phase 1/2Results posted
• Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast CancerCompletedNCT00057941Phase 2Results posted
• Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast CancerCompletedNCT00054132Phase 2Results posted
• Suramin and Paclitaxel in Treating Women With Stage IIIB-IV Breast CancerCompletedNCT00054028Phase 1/2Results posted
• Vaccine and Chemotherapy for Previously Untreated Metastatic Breast CancerTerminatedNCT00048893Phase 1/2Results posted
• Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast CancerCompletedNCT00005908Phase 2Results posted